PsyBio Therapeutics Corp., a biotechnology company, develops formulations of psychoactive medications produced by genetically modified bacteria for the treatment of mental health and other disorders in the United States. It also engages in the research and development of naturally occurring tryptamines in varieties of hallucinogenic mushrooms, other tryptamines, phenethylamines, and combinations; and new molecular structures that do not occur in nature, which have therapeutics properties. The company is based in Coconut Creek, Florida.
This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol PSYBF.
This company has cross-listed shares that trade in the U.S. as the symbol PSYBF.
0.07 CAD
As of 05/13/2022
2022 © Stock Market MBA, Inc.